[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
3. Rajput DK, Mehrotra A, Srivastav AK, Kumar R, Mahapatra AK: Bilateral thalamic glioma in a 6-year-old child. J Pediatr Neurosci; 2010 Jan;5(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic glioma in a 6-year-old child.
  • Bithalamic gliomas are extremely rare tumors of central nervous system.
  • Although they are usually benign in nature, their outcome is poor because of the involvement of thalamic nuclei and inadequate surgical excision.
  • Surgery is usually done to get tissue for diagnosis.
  • Role of radiotherapy and chemotherapy is questionable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042509.001).
  • [ISSN] 1998-3948
  • [Journal-full-title] Journal of pediatric neurosciences
  • [ISO-abbreviation] J Pediatr Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2964793
  • [Keywords] NOTNLM ; Bithalamic gliomas / thalamic gliomas
  •  go-up   go-down


Advertisement
4. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down


7. Rilliet B, Vernet O: Gliomas in children: a review. Childs Nerv Syst; 2000 Nov;16(10-11):735-41
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomas in children: a review.
  • The management and prognosis of gliomas are significantly different in children and in adults.
  • Fortunately, the proportion of gliomas that are malignant is smaller in children than in the adult population.
  • The different types of gliomas encountered in the pediatric population are reviewed, taking account of the most recent contributions on this subject.
  • A brief review of the possible causes of gliomas is presented.
  • Unfortunately, the information obtained by molecular and genetic study of these tumors has still not resulted in anything that can help the children suffering from gliomas in a concrete way.
  • Surgery, with all its recent refinements, remains the best treatment for the majority of benign gliomas providing they can be removed without unacceptable sequelae.
  • The role of chemotherapy has emerged recently for the treatment of nonresectable low-grade gliomas, such as hypothalamic-chiasmatic tumors, especially for infants, in whom the adverse effects of radiotherapy can be severe and irreversible.
  • On the eve of the new millennium, there is renewed hope that the problem of malignant gliomas will be solved in the not-too-distant future.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11151725.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 55
  •  go-up   go-down


8. Desjardins L: [Ophthalmological tumors in children: diagnosis and therapeutic strategy]. J Fr Ophtalmol; 2000 Nov;23(9):926-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ophthalmological tumors in children: diagnosis and therapeutic strategy].
  • The principles of the treatment of retinoblastoma are exposed especially the side effects of radiotherapy that lead to a limitation of the use of external beam if possible.
  • Treatments methods include external beam radiotherapy, chemotherapy, thermochemotherapy cryotherapy, curietherapy and photocoagulation.
  • Results and indications of these treatments are given.
  • The main orbital benign and malignant tumors and their treatment are listed: orbital cyst, neurofibroma; optic nerve gliomas; rhabdomyosarcomas, bone tumors and metastatic tumors.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Orbital Neoplasms / therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Brachytherapy. Child. Child, Preschool. Cryotherapy. Diagnosis, Differential. Exophthalmos / etiology. Female. Follow-Up Studies. Humans. Male. Radiotherapy Dosage. Retinal Diseases / diagnosis. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11084454.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


9. Massimi L, Tufo T, Di Rocco C: Management of optic-hypothalamic gliomas in children: still a challenging problem. Expert Rev Anticancer Ther; 2007 Nov;7(11):1591-610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of optic-hypothalamic gliomas in children: still a challenging problem.
  • Optic pathway-hypothalamic gliomas (OPHGs) are rare, often unresectable tumors that mostly occur in childhood.
  • Their biological behavior is unpredictable, although they tend to follow an aggressive clinical course in infants and a benign course in children with neurofibromatosis type 1.
  • Chemotherapy is increasingly used in the management of OPHGs, especially in infants, to delay radiotherapy.
  • Carboplatin and vincristine are the most frequently used drugs, although several chemotherapeutic agents in different combinations are currently employed with good results.
  • [MeSH-major] Hypothalamic Neoplasms / therapy. Optic Nerve Glioma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18020927.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 148
  •  go-up   go-down


10. Bowers DC, Georgiades C, Aronson LJ, Carson BS, Weingart JD, Wharam MD, Melhem ER, Burger PC, Cohen KJ: Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg; 2000 Jan;32(1):24-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tectal gliomas: natural history of an indolent lesion in pediatric patients.
  • The mesencephalic tectal glioma is a distinctive form of brain stem glioma with an unusually benign clinical course.
  • The clinical management of these lesions, especially at the time of radiographic enlargement varies widely in the published literature.
  • One of these 6 patients had radiographic progression coupled with a new clinical symptom which was treated with stereotactic radiation therapy.
  • The results suggest that pediatric tectal gliomas are a very low-grade lesion.
  • Conservative management in the absence of new clinical symptoms could be argued, reserving radiotherapy or chemotherapy for clinical progression.
  • [MeSH-minor] Adolescent. Age of Onset. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10765135.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Hargrave D: Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg; 2009 Aug;23(4):351-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
  • Gliomas are the most common type of paediatric brain tumour and range from benign low grade gliomas which can be resected/observed to aggressive brainstem gliomas with dismal survival rates.
  • Current therapies rely on neurosurgery, radiotherapy, chemotherapy or combination of these conventional modalities and although histopathology helps to direct therapy, molecular pathology has so far not played a major role in the management of paediatric glioma.
  • However, increasing knowledge of glioma biology is starting to impact on drug development towards targeted therapies.
  • The molecular biology of adult malignant glioma is now well described and targeted therapies against VEGFR are already playing a role in the management of glioblastoma.
  • It is likely that high grade gliomas in children and adults share common aberrant molecular pathways but the frequency and mechanisms involved probably will exhibit key differences and on-going comprehensive molecular analyses of paediatric high grade glioma are essential to determine which targets are important in children.
  • However, selection for specific targeted therapy is unlikely to be based on, or restricted by, age but will require individual case by case testing for target presence in order to direct and maximise the efficacy of molecular therapy.
  • Brainstem glioma remains a tumour with a dismal prognosis but relatively little is known about the underlying biology and progress will require a concerted effort to collect tissue by biopsy and autopsy to allow appropriate analysis to identify and validate targets.
  • A new era of molecular based therapies offers the promise of major benefits in the management of paediatric glioma but translating this promise into reality will require further understanding of the biology driving these tumours.
  • [MeSH-major] Brain Neoplasms. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / genetics. Astrocytoma / pathology. Astrocytoma / therapy. Child. Child, Preschool. Combined Modality Therapy. Drug Delivery Systems. Genetic Predisposition to Disease. Genome-Wide Association Study. Hamartoma Syndrome, Multiple / genetics. Humans. Infant. Neoplasm Staging. Neurofibromatosis 1 / genetics. Prognosis. Tuberous Sclerosis / genetics


12. Raco A, Raimondi AJ, D'Alonzo A, Esposito V, Valentino V: Radiosurgery in the management of pediatric brain tumors. Childs Nerv Syst; 2000 May;16(5):287-95
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 114 patients with benign and malignant intracranial tumors were treated by Valentino at the Flaminia Radiosurgical Center using a Philips 6-MeV linear accelerator between 1987 and 1995.
  • Seventy-nine patients had multivariate/combined treatment consisting of surgery or biopsy followed by chemotherapy, radiotherapy and/or radiosurgery.
  • Thirty-five were not operated on or biopsied but were treated primarily by radiosurgery, which was associated with chemotherapy and conventional radiotherapy.
  • The short- and long-term results were evaluated separately for each pathology in an attempt to derive guidelines for future treatment.
  • For tumors of the pineal region, we are of the opinion that radiosurgery is the treatment of choice in children and that more than one-third of patients can be cured by this means.
  • The remaining patients require surgery and/or chemotherapy in addition.
  • For medulloblastomas radiosurgery may be useful to control local recurrence if coupled with chemotherapy.
  • We fear that limiting treatment to radiosurgery, rather than prescribing conventional radiotherapy when indicated, could permit CNS seeding.
  • In glial tumors radiosurgery helped either to "sterilize" the tumor bed after removal or to treat remnants of the lesions in critical areas; for diffuse brain stem gliomas it should be considered the treatment of choice.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoplasm Recurrence, Local. Neoplasm Seeding. Neoplasm, Residual / surgery. Prognosis. Radiotherapy. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883372.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


13. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol; 2009 May 20;27(15_suppl):2062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2062 Background: No effective treatment is available for recurrent meningiomas when surgical and radiation options are exhausted.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • METHODS: Patients with recurrent histologically confirmed meningiomas and no more than two previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and eight (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 29%, 12-month PFS (PFS12) 0%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • Treatment was well-tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wang HC, Hertzog JH, O'Donnell HD, Walter AW: Natural progression of an unresected supratentorial ependymoma. Pediatr Neurosurg; 2008;44(1):75-8
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas are rare gliomas that have been associated with a poor outcome despite aggressive therapy including surgery, chemotherapy and radiation therapy.
  • Our case report suggests that the improved outcome may be due in part to the biologically benign nature of some supratentorial ependymomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18097198.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Rosser T, Packer RJ: Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol; 2002 Aug;17(8):630-7; discussion 646-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis 1 is associated with an increased risk for the development of benign and malignant tumors involving neural and non-neural tissues.
  • Optic pathway gliomas and brainstem gliomas are the most common intracranial neoplasms found in neurofibromatosis 1, although there also is an increased incidence of other brain tumors in this population.
  • The majority of these intracranial neoplasms are benign pilocytic astrocytomas, which may behave in a less aggressive manner than histologically identical tumors in non-neurofibromatosis 1 patients.
  • When intervention is required, conventional treatment with surgery, radiation, or chemotherapy has been used with variable results.
  • The current challenge lies in understanding the pathogenesis of gliomas in neurofibromatosis 1, which may lead to the development of biologically directed therapies with less associated morbidity and mortality for neurofibromatosis 1 as well as non-neurofibromatosis 1 children.
  • [MeSH-minor] Brain / pathology. Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / genetics. Brain Stem Neoplasms / therapy. Child. Glioma / diagnosis. Glioma / genetics. Glioma / therapy. Humans. Optic Nerve / pathology. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / genetics. Optic Nerve Glioma / therapy. Risk

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12403562.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


16. Kantar M, Cetingül N, Kansoy S, Anacak Y, Demirtaş E, Erşahin Y, Mutluer S: Radiotherapy-induced secondary cranial neoplasms in children. Childs Nerv Syst; 2004 Jan;20(1):46-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors usually occur in a different site from the primary brain tumor several years after treatment.
  • CASE REPORT: We report secondary cranial malignant neoplasms in three patients who were treated with irradiation and chemotherapy for their primary brain tumors.
  • The first case is a male survivor of an orbital rhabdomyosarcoma who developed a meningioma 8 years later.
  • The other two cases are female survivors of ependymomas who were irradiated at the age of 3 and developed secondary gliomas 8 and 17 years after therapy respectively.
  • CONCLUSION: Patients carry a risk of developing SMNs many years later since irradiation is still an important part of the treatment.
  • An SMN may have a benign course, as in meningioma, or be a dilemma for the patient, as in glioblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2001 Sep;31(9):607-9 [11511997.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):271-9 [2693630.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Med Pediatr Oncol Suppl. 1996;1:29-34 [8643045.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17(5):362-8 [11642493.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • (PMID = 14714135.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / S100 Proteins
  •  go-up   go-down


17. Konovalov AN, Pitskhelauri DI: Principles of treatment of the pineal region tumors. Surg Neurol; 2003 Apr;59(4):250-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment of the pineal region tumors.
  • BACKGROUND: A pineal region tumor is an uncommon deep-seated, heterogeneous group of mass lesions of the brain, and the management strategy of any types of these tumors remains controversial.
  • Radiation therapy was administered in 145 (51%) and chemotherapy in 16 patients.
  • The projected 5-year and 10-year survival rates for patients with malignant pineal tumors, who received irradiation after tumor resection or underwent radiation therapy alone, were: 95% and 88% for pure germinomas, 80% and 50% for high grade gliomas, 44% and 0% for malignant pineal parenchymal tumors, and 20% and 0% for malignant germ cell tumors, respectively.
  • CONCLUSIONS: Benign pineal tumors should be cured with surgery alone.
  • Malignant tumors should be treated with aggressive resection followed with irradiation and chemotherapy.
  • Pure germinomas, which are exquisitely radiosensitive, can be cured by conventional radiation therapy alone.
  • [MeSH-major] Germinoma / surgery. Glioma / surgery. Pinealoma / surgery
  • [MeSH-minor] Adolescent. Adult. Animals. Biopsy. Child. Child, Preschool. Female. Humans. Hydrocephalus / etiology. Male. Middle Aged. Prognosis. Retrospective Studies. Stereotaxic Techniques. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748006.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Castro MG, Cowen R, Smith-Arica J, Williams J, Ali S, Windeatt S, Gonzalez-Nicolini V, Maleniak T, Lowenstein PR: Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas. Histol Histopathol; 2000 Oct;15(4):1233-52
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas.
  • Intracranial tumours such as brain gliomas and pituitary adenomas pose a challenging area of research for the development of gene therapy strategies, both from the point of view of the severity of the diseases, to the physiological implication of gene delivery into the central nervous system and pituitary gland.
  • On the one hand, brain gliomas are very malignant tumours, with a life expectancy of six months to a year at the most after the time of diagnosis, in spite of advances in treatment modalities which involve chemotherapy, surgery and radiotherapy.
  • Gene therapy for these tumours is therefore a very attractive therapeutic modality which due to the severity of the disease is already in clinical trials.
  • On the other hand, pituitary tumours are usually benign, and in most cases, treatment is successful.
  • Nevertheless, there are some instances, especially with the macroadenomas and some invasive tumours in which treatment fails.
  • Gene therapy strategies for these adenomas therefore needs to progress substantially in terms of safety, adverse side effects and physiological impact on the normal pituitary gland before clinical implementation.
  • In this paper, we will review gene delivery systems both viral and non-viral and several therapeutic strategies which could be implemented for the treatment of these diseases.
  • We will also review the models which are currently available in which these gene therapy strategies can be tested experimentally.
  • This new therapeutic modality holds enormous promise, but we still need substantial improvements both from the delivery, efficacy and safety stand points before it can become a clinical reality.
  • [MeSH-major] Adenoma / therapy. Brain Neoplasms / therapy. Genetic Therapy. Glioma / therapy. Pituitary Neoplasms / therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005248.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 115
  •  go-up   go-down


19. Wabbels B, Demmler A, Seitz J, Woenckhaus M, Bloss HG, Lorenz B: Unilateral adult malignant optic nerve glioma. Graefes Arch Clin Exp Ophthalmol; 2004 Sep;242(9):741-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for optic nerve glioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral adult malignant optic nerve glioma.
  • INTRODUCTION: Adult malignant optic nerve gliomas are rare and rapidly fatal visual pathway tumours.
  • They represent a clinical entity different from the more common childhood benign optic nerve gliomas, which are frequently associated with neurofibromatosis I.
  • Clinical and MRI evaluation of the left eye and optic nerve were normal at all times.
  • DISCUSSION: Unilateral adult malignant glioma of the optic nerve is exceptional.
  • To date, 44 case reports of adult malignant optic nerve glioma have been published, either malignant astrocytoma or glioblastoma.
  • On MRI images, malignant glioma cannot be distinguished from optic nerve enlargement due to other causes.
  • Although radiotherapy appears to prolong life expectancy, all presently available treatment options (radiation, surgery, radio-chemotherapy) are of limited value.
  • [MeSH-major] Optic Nerve Glioma / pathology. Optic Nerve Neoplasms / pathology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1949 Nov;33(11):701-8, illust [15406720.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):731-5 [718470.001]
  • [Cites] Neurosurg Rev. 1995;18(4):273-5 [8927245.001]
  • [Cites] J Clin Neuroophthalmol. 1985 Dec;5(4):238-43 [3001150.001]
  • [Cites] Br J Ophthalmol. 1967 Oct;51(10):703-6 [6054905.001]
  • [Cites] Am J Ophthalmol. 1980 Feb;89(2):284-92 [6243868.001]
  • [Cites] Br J Ophthalmol. 1973 Oct;57(10):788-91 [4361475.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1 Suppl):110 [12546402.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):923-5 [7472567.001]
  • [Cites] J Neuroophthalmol. 2001 Mar;21(1):1-7 [11315972.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1987;224:59-60 [3509024.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Surg Neurol. 1984 Jan;21(1):83-7 [6689816.001]
  • [Cites] Neurosurgery. 1982 Dec;11(6):787-9 [6298650.001]
  • [Cites] Minn Med. 1982 Mar;65(3):155-9 [7087953.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):277-9 [2643688.001]
  • [Cites] Neurology. 1988 Jul;38(7):1071-4 [3386825.001]
  • [Cites] Arch Ophthalmol. 1976 Jul;94(7):1142-4 [180944.001]
  • [Cites] Brain. 1973;96(1):121-32 [4695718.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):1046-8 [9672989.001]
  • [Cites] Acta Neurol Scand. 1999 Nov;100(5):350-3 [10536925.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1673-6 [7502973.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Br J Ophthalmol. 1973 Apr;57(4):253-64 [4707622.001]
  • [Cites] J Neurosurg. 1996 May;84(5):898-9 [8622175.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • (PMID = 15085353.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 29
  •  go-up   go-down


20. Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven Vv, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C: The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie; 2005 Jan;28(1):22-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This group was composed of 4 subgroups: 28% benign skull base tumors (19% meningiomas, 4% pituitary adenomas, 3% acoustic schwannomas, 2% others), 24% primary brain tumors of glial origin (8% glioblastomas, 12% gliomas other than glioblastomas, 5% oligoastrocytomas or oligodendrogliomas), 19% brain metastases, and 8% other brain or skull base tumors.
  • The recommendations given by the BTB included: 23% further diagnostic procedures (11% non-invasive examinations, 12% stereotactic biopsies), 57% active antitumoral therapy (22% resection, 17% fractionated radiotherapy, 13% radiosurgery, 5% chemotherapy, <1% embolization), 20% no treatment (14% watchful waiting, 6% supportive care).
  • CONCLUSION: Interdisciplinary care seems to be particularly necessary in patients with benign skull base tumors, gliomas and brain metastases.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials Data Monitoring Committees / statistics & numerical data. Decision Support Systems, Clinical / statistics & numerical data. Outcome Assessment (Health Care). Patient Care Team / statistics & numerical data. Quality Assurance, Health Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15616378.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Baldari S, Restifo Pecorella G, Cosentino S, Minutoli F: Investigation of brain tumours with (99m)Tc-MIBI SPET. Q J Nucl Med; 2002 Dec;46(4):336-45
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elements determining MIBI uptake at the level of the brain are first mentioned. (99m)Tc-MIBI SPET features in different malignant and benign brain lesions (low and high grade gliomas, glioblastoma multiforme, metastasis, lymphoma, meningioma, neuroma, radiation necrosis and other rarer brain lesions) are reviewed.
  • In addition the relationships among (99m)Tc-MIBI SPET, P-glycoprotein (MDR-1 gene product) expression in brain neoplasms and chemotherapy response are mentioned.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Brain Neoplasms / therapy. Technetium Tc 99m Sestamibi

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12411875.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  • [Number-of-references] 71
  •  go-up   go-down


22. Vaillant B, Loghin M: Treatment of spinal cord tumors. Curr Treat Options Neurol; 2009 Jul;11(4):315-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of spinal cord tumors.
  • The timeliness of diagnosis of spinal cord tumors and promptness of treatment are important, as they directly affect outcome.
  • Dexamethasone, a corticosteroid, is used as a temporizing measure to improve or stabilize neurologic function until definitive treatment.
  • For nonambulatory patients with epidural metastatic tumors, surgery followed by radiation therapy maximizes neurologic function and modestly lengthens survival.
  • An ambulatory patient with a stable spine should be considered for radiation treatment only.
  • The role of chemotherapy for epidural metastatic tumors is not well established.
  • For intramedullary metastases, the role of surgery and chemotherapy remains controversial and radiation is the mainstay.
  • For low-grade or benign primary spinal cord tumors, resective surgery is of benefit and can be curative.
  • For high-grade tumors, the benefit of resection is less clear, and radiotherapy and/or chemotherapy may be helpful.
  • The use of chemotherapy for primary spinal cord tumors has rarely been assessed.
  • Agents reported in the literature for treatment of spinal cord gliomas include temozolomide, irinotecan, cisplatin, and carboplatin.
  • A multidisciplinary approach is often required to maximize the therapeutic and functional outcome of patients with metastatic and primary spinal cord tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2008 Jan;10(1):78-85 [18366964.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Dec;60(3):194-200 [16949298.001]
  • [Cites] Postgrad Med J. 2008 Aug;84(994):418-27 [18832403.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3):312-23 [16769420.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):375-83 [15637649.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):35-45 [17196509.001]
  • [Cites] Neurosurg Clin N Am. 2004 Oct;15(4):549-64 [15450889.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2028-37 [15774794.001]
  • [Cites] Lancet Neurol. 2008 May;7(5):459-66 [18420159.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3879-85 [18688056.001]
  • [Cites] Eur Spine J. 2006 Feb;15(2):203-10 [16374649.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):937-46 [18314436.001]
  • [Cites] J Neurooncol. 2000 May;47(3):219-24 [11016738.001]
  • [Cites] Eur Spine J. 2007 Mar;16(3):399-404 [16865377.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):64-76 [15701283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] J Neurooncol. 2008 Apr;87(2):173-9 [18084720.001]
  • [Cites] J Surg Oncol. 2007 Apr 1;95(5):419-26 [17345619.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3358-65 [15738534.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):208-13 [12816727.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Oct 08;(4):CD006716 [18843728.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3):311-21 [10864219.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):157-61 [17948910.001]
  • [Cites] Neuroradiology. 2008 Apr;50(4):301-14 [18084751.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):85-9 [17310265.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):643-8 [16112300.001]
  • [Cites] Neurosurg Clin N Am. 2006 Jan;17(1):45-50 [16448907.001]
  • [Cites] Oncologist. 2008 Sep;13(9):967-77 [18776058.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3388-93 [16849752.001]
  • (PMID = 19523357.001).
  • [ISSN] 1092-8480
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Yokoo H, Kamiya M, Sasaki A, Hirato J, Nakazato Y, Kurachi H: Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression. Pathol Int; 2001 Jul;51(7):570-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression.
  • Patients with neurofibromatosis type 1 (NF1) often have gliomas as a complication, most of which are benign pilocytic astrocytomas which have arisen in optic pathways.
  • Partially resected tissue samples showed pleomorphic astrocytoma with abundant xanthoma cells and degenerative structures such as Rosenthal fibers (RF) and eosinophilic granular bodies.
  • Partially resected tumor tissues were composed of monotonous small anaplastic cells with prominent proliferative activity.
  • Postoperative chemotherapy with procarbazine, MCNU and vincristine (PCV) suppressed the residual tumor dramatically, but the regrowing tumor finally became uncontrollable, leading to the patient's death.
  • A review of previously published reports failed to reveal any cases of this type.
  • [MeSH-minor] Adolescent. Antigens, Nuclear. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA Primers / chemistry. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Microfilament Proteins / analysis. Neoplasm Recurrence, Local. Neoplasms, Second Primary / pathology. Nitrosourea Compounds / therapeutic use. Nuclear Proteins / analysis. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Procarbazine / therapeutic use. Tumor Suppressor Protein p53 / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11472572.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Nitrosourea Compounds; 0 / Nuclear Proteins; 0 / Tagln protein, mouse; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


24. Harrer JU, Mayfrank L, Mull M, Klötzsch C: Second harmonic imaging: a new ultrasound technique to assess human brain tumour perfusion. J Neurol Neurosurg Psychiatry; 2003 Mar;74(3):333-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Second harmonic imaging is a new ultrasound technique that allows evaluation of brain tissue perfusion after application of an ultrasound contrast agent.
  • These were divided into four groups: gliomas, WHO grade III-IV (n = 6); meningiomas (n = 9); metastases (n = 5); and others (n = 7).
  • Following intravenous administration of 4 g (400 mg/ml) of a galactose based echo contrast agent, 62 time triggered images (one image per 2.5 seconds) were recorded and analysed off-line.
  • Time-intensity curves of two regions of interest (tumour tissue and healthy brain tissue), including peak intensity (PI) (dB), time to peak intensity (TP) (s), and positive gradient (PG) (dB/s), as well as ratios of the peak intensities of the two regions of interest, were derived from the data and compared intraindividually and interindividually.
  • RESULTS: After administration of the contrast agent a marked enhancement of echo contrast was visible in the tumour tissue in all patients.
  • Mean PI and PG were significantly higher in tumour tissue than in healthy brain parenchyma (11.8 v 5.1 dB and 0.69 v 0.16 dB/s; p < 0.001).
  • A tendency towards higher PI and PG as well as shorter TP was apparent in malignant gliomas.
  • When comparing different tumour types, however, none of these variables reached significance, nor were there significant differences between malignant and benign tumours in general.
  • CONCLUSIONS: Second harmonic imaging not only allows identification of brain tumours, but may also help in distinguishing between different tumour types.
  • Further studies are needed to evaluate the clinical potential of this technique in investigating brain tumours-for example in follow up investigations of patients undergoing radiation or chemotherapy-especially in comparison with neuroradiological and neuropathological findings.
  • [MeSH-major] Brain Neoplasms. Glioma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Heart. 1999 Jun;81(6):636-41 [10336924.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):616-22 [11032613.001]
  • [Cites] Neurology. 1996 Oct;47(4):993-8 [8857733.001]
  • [Cites] Radiology. 2000 Aug;216(2):592-6 [10924591.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] Neurosurgery. 1999 Mar;44(3):469-77; discussion 477-8 [10069583.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):131-8 [11191052.001]
  • [Cites] Keio J Med. 2000 Feb;49 Suppl 1:A16-24 [10750329.001]
  • [Cites] Stroke. 2002 Jun;33(6):1530-5 [12052986.001]
  • [Cites] Magn Reson Med. 2001 Aug;46(2):228-39 [11477625.001]
  • [Cites] BMJ. 2001 May 19;322(7296):1222-5 [11358777.001]
  • [Cites] J Neuroimaging. 2001 Jan;11(1):18-24 [11198522.001]
  • [Cites] J Neuroimaging. 2001 Jul;11(3):287-92 [11462296.001]
  • [Cites] Semin Liver Dis. 2001 May;21(2):147-59 [11436569.001]
  • [Cites] J Am Coll Cardiol. 1997 Mar 15;29(4):791-9 [9091526.001]
  • [Cites] Neurol Res. 2000 Jul;22(5):457-64 [10935216.001]
  • [Cites] Ultrasound Med Biol. 2000 Jul;26(6):965-75 [10996696.001]
  • [Cites] Invest Radiol. 2000 Jan;35(1):58-71 [10639037.001]
  • [Cites] Ultrasonics. 1991 Jul;29(4):324-30 [2058051.001]
  • [Cites] Eur J Ultrasound. 2001 Dec;14(2-3):103-13 [11704427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):565-71 [10837937.001]
  • [Cites] Stroke. 1998 Sep;29(9):1901-7 [9731616.001]
  • [Cites] Ultrasound Med Biol. 2000 Jun;26(5):807-18 [10942828.001]
  • [Cites] Eur J Ultrasound. 1999 May;9(2):167-75 [10413753.001]
  • [Cites] J Nucl Med. 2001 Apr;42(4):611-23 [11337551.001]
  • [Cites] Radiology. 2000 Apr;215(1):153-61 [10751481.001]
  • [Cites] Clin Radiol. 1996 Feb;51 Suppl 1:50-5 [8605774.001]
  • [Cites] Cancer Control. 1998 Mar;5(2):115-123 [10761022.001]
  • [Cites] Radiology. 2000 Aug;216(2):411-7 [10924562.001]
  • [Cites] Nervenarzt. 1993 Dec;64(12):766-9 [8114977.001]
  • [Cites] Ultrasound Med Biol. 1993;19(7):567-79 [8310553.001]
  • (PMID = 12588918.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1738355
  •  go-up   go-down


25. Hughes SA, Achanta P, Ho AL, Duenas VJ, Quiñones-Hinojosa A: Biological horizons for targeting brain malignancy. Adv Exp Med Biol; 2010;671:93-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though currently available clinical treatments and therapies have clearly extended the survival of patients with brain tumors, many of these advances are short lived, particularly with respect to high grade gliomas such as glioblastoma multiforme.
  • The missing link to an efficacious treatment of high grade gliomas is a more complete understanding of the basic molecular and cellular origin of brain tumors.
  • However, new discoveries of stem cell and developmental neurobiology have now borne the cancer stem cell hypothesis, drawing off of intriguing similarities between benign and malignant cells within the central nervous system.
  • "Molecular neurosurgery", glioma treatments involving biologics using neural stem cells to target the cancer at the level of individual migratory cell, is a rapidly evolving field.
  • [MeSH-major] Brain Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Drug Delivery Systems. Genetic Therapy / methods. Glioma / pathology. Glioma / therapy. Neurons / physiology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455498.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M: Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med; 2008 Dec;8(8):711-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-invasive energy metabolism measurements in brain tumors in vivo are now performed widely as molecular imaging by positron emission tomography.
  • This capability has developed from a large number of basic and clinical science investigations that have cross fertilized one another.
  • Apart from precise anatomical localization and quantification, the most intriguing advantage of such imaging is the opportunity to investigate the time course (dynamics) of disease-specific molecular events in the intact organism.
  • Common clinical indications for molecular imaging of primary brain tumors therefore contain (i) primary brain tumor diagnosis, (ii) identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), and (iii) prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • Molecular imaging may identify early disease and differentiate benign from malignant lesions.
  • Moreover, an early identification of treatment effectiveness could influence patient management by providing objective criteria for evaluation of therapeutic strategies for primary brain tumors.
  • Specially, its novel potential to visualize metabolism and signal transduction to gene expression is used in reporter gene assays to trace the location and temporal level of expression of therapeutic and endogenous genes.
  • The authors present here illustrative data of PET imaging: the thymidine kinase gene expression in experimentally transplanted F98 gliomas in cat brain indicates, that [(18)F]FHBG visualizes cells expressing TK-GFP gene in transduced gliomas as well as quantities and localizes transduced HSV-1-TK expression if the blood brain barrier is disrupted.
  • The higher uptake of [(18)F]FLT in the wild-type compared to the transduced type may demonstrate the different doubling time of both tumor tissues suggesting different cytosolic thymidine kinase activity.
  • Molecular imaging probes are developed to image the function of targets without disturbing them or as drug in oder to modify the target's function.
  • This is transfer of gene therapy's experimental knowledge into clinical applications.
  • [MeSH-minor] Animals. Capillary Permeability. Diagnosis, Differential. Drug Discovery. Gene Expression. Genes, Reporter. Genetic Therapy. Humans. Neovascularization, Pathologic. Positron-Emission Tomography / methods. Signal Transduction. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075670.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase
  • [Number-of-references] 158
  •  go-up   go-down


27. Kiwerski JE: Surgery and subsequent rehabilitation for cervical spine tumours compressing neural structures. Ortop Traumatol Rehabil; 2008 Nov-Dec;10(6):620-5
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the cervical spine is also the site of benign tumours and neoplasms involving not only bony tissue.
  • Benign tumours do not metastasize but pose a threat to the spinal cord when located intrathecally.
  • The most common cervical spine neoplasms are intradural tumours, usually extramedullary: neurofibromas, meningiomas or gliomas.Indications for surgery depend of the nature and location of the tumour and the consequences of tumour growth.
  • The choice of surgical approach and manner of stabilisation depend primarily on the location of the lesion and the presence of spinal cord compression.Rehabilitation is indicated in all patients, but is particularly important, and at the same time difficult, when the growth of the tumour has resulted in neurological disturbances.
  • Rehabilitation programmes should be designed individually for each patient and should account for the degree of paresis, stage of the underlying malignant disease, survival prognosis, disturbances in the function of other systems, apart from musculoskeletal apparatus, age of the patient, his or her commitment to treatment and other factors.The treatment of malignant neoplasms is usually associated with an unfavourable outcome.
  • However, combination drug treatments, radiation therapy and surgery with subsequent rehabilitation will often prolong survival, ameliorate suffering and improve patients' quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274865.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 16
  •  go-up   go-down


28. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type serine proteinase inhibitor.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Malignant meningiomas constitute 10-15% of all meningiomas and our previous studies revealed loss of expression of TFPI-2 in malignant gliomas.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


29. Korf BR: Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep; 2001 Mar;1(2):162-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of neurofibromatosis type 1.
  • Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder whose major feature is the occurrence of multiple neurofibromas, which are benign tumors of the nerve sheath.
  • In addition to neurofibromas, there are many other clinical manifestations, including malignant tumors such as gliomas or malignant peripheral nerve sheath tumors, and nontumor effects such as skeletal dysplasia and learning disability.
  • Heterozygous effects on some cell types are also likely, however.
  • The role of ras in the pathogenesis of tumors in NF1 has suggested an approach to treatment using ras inhibitors, some of which are likely to begin in clinical trials in NF1 patients in the near future.
  • [MeSH-major] Neurofibromatosis 1 / therapy
  • [MeSH-minor] Animals. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Cafe-au-Lait Spots / etiology. Cell Transformation, Neoplastic / genetics. Female. Genes, Dominant. Genes, Neurofibromatosis 1. Glioma / etiology. Glioma / pathology. Glioma / therapy. Guanosine Triphosphate / metabolism. Humans. Hypertension / drug therapy. Hypertension / etiology. Learning Disorders / etiology. Learning Disorders / therapy. Leukemia / etiology. Leukemia / therapy. Male. Mice. Mice, Knockout. Neurofibroma / etiology. Neurofibroma / pathology. Neurofibroma / therapy. Neurofibromin 1 / chemistry. Neurofibromin 1 / physiology. Protein Structure, Tertiary. Rhabdomyosarcoma / etiology. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Scoliosis / etiology. Scoliosis / pathology. ras Proteins / metabolism

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 1999 Jun;103(6 Pt 1):1257-62 [10353939.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2469-76 [10498620.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):181-8 [10620616.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):190-3 [10218464.001]
  • [Cites] J Child Neurol. 2000 Mar;15(3):157-60 [10757470.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):393-401 [10677298.001]
  • [Cites] Genomics. 2000 May 15;66(1):93-7 [10843809.001]
  • [Cites] J Psychiatr Res. 1999 Jan-Feb;33(1):63-8 [10094241.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]
  • [Cites] J Child Neurol. 2000 Apr;15(4):235-8 [10805189.001]
  • [Cites] J Pediatr Orthop B. 2000 Jan;9(1):3-10 [10647102.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] J Pediatr. 1999 Jun;134(6):767-72 [10356149.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):398-402 [10469340.001]
  • [Cites] Dev Neuropsychol. 2000;17(1):29-47 [10916573.001]
  • [Cites] J Invest Dermatol. 1999 Jun;112(6):835-42 [10383727.001]
  • [Cites] Hum Mol Genet. 2000 Apr 12;9(7):1059-66 [10767330.001]
  • [Cites] Surg Neurol. 1999 Feb;51(2):211-8 [10029430.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):283-5 [10451710.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7 [10675220.001]
  • [Cites] Neuroradiology. 1999 Sep;41(9):625-9 [10525761.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Am J Med Genet. 2000 Jul 17;93(2):136-42 [10869117.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Am J Med Genet. 1999 Dec 3;87(4):317-23 [10588837.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):608-14 [10699117.001]
  • [Cites] Am J Med Genet. 1999 Jun 11;84(5):413-9 [10360395.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1646-51 [10762507.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):35-46 [10587576.001]
  • [Cites] Pediatrics. 1999 Oct;104(4):e49 [10506274.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Neurology. 2000 Feb 22;54(4):914-20 [10690986.001]
  • [Cites] Acta Orthop Scand. 1999 Jun;70(3):275-82 [10429605.001]
  • [Cites] Am J Med Genet. 2000 May 29;92(3):224-8 [10817659.001]
  • [Cites] Pediatr Radiol. 1999 May;29(5):353-6 [10382213.001]
  • [Cites] J Child Neurol. 2000 Feb;15(2):90-6 [10695893.001]
  • [Cites] Arch Neurol. 1999 Nov;56(11):1343-6 [10555653.001]
  • [Cites] J Biomed Sci. 2000 Jul-Aug;7(4):292-8 [10895051.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):100-9 [10631140.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Jan;25(1):69-75 [10647163.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):895-8 [10706287.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Am J Hum Genet. 2000 Jun;66(6):1969-74 [10775528.001]
  • [Cites] J Neurooncol. 1999;45(2):185-90 [10778734.001]
  • [Cites] Hum Mutat. 1999;14(5):387-93 [10533064.001]
  • [Cites] Eur J Hum Genet. 2000 Jun;8(6):455-9 [10878667.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):189-95 [10678181.001]
  • (PMID = 11898512.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 86-01-1 / Guanosine Triphosphate; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 53
  •  go-up   go-down


30. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery; 2000 Apr;46(4):938-47; discussion 947-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The understanding of angiogenic mechanisms could offer new therapeutic perspectives; in this context, the role of four potentially angiogenic growth factors was analyzed in a large series of meningiomas of different grades.
  • RESULTS: Tumors included 40 benign (World Health Organization [WHO] Grade I), 21 atypical (WHO Grade II), and 8 anaplastic/malignant (WHO Grade III) meningiomas.
  • We found a correlation between meningioma grade and VEGF content (r = 0.37, P = 0.002), which was 2-fold higher in atypical than in benign meningiomas (P = 0.022) and 10-fold higher in malignant than in benign meningiomas (P = 0.025).
  • CONCLUSION: Meningiomas do not show an angiogenic switch involving VEGF and/or hepatocyte growth factor/scatter factor, as has previously been found in gliomas.
  • Nevertheless, the biological activity of VEGF and basic fibroblast growth factor in meningiomas suggests that both are potential targets for antiangiogenic therapy in meningiomas of all WHO grades.
  • [MeSH-minor] Chemotaxis. Endothelium, Vascular / drug effects. Endothelium, Vascular / pathology. Endothelium, Vascular / physiopathology. Humans. Neoplasm Invasiveness. Neovascularization, Pathologic / chemically induced. Neovascularization, Pathologic / pathology. Tissue Extracts / pharmacology. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764269.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Pregnancy Proteins; 0 / Tissue Extracts; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 144589-93-5 / placenta growth factor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


31. Siomin V, Angelov L, Li L, Vogelbaum MA: Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol; 2005 Sep;74(2):211-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors.
  • INTRODUCTION: The American Association of Neurology issued guidelines discouraging the prophylactic use of anti-epilepsy drugs (AEDs) in patients with brain tumors.
  • More than 70% of respondents reported routine use of AED prophylaxis for patients with intra-axial gliomas or brain metastases.
  • AED prophylaxis was also routinely used for extra-axial benign tumors or stereotactic biopsies by 53.8% and 21.4%, respectively.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / drug therapy. Epilepsy / drug therapy. Neurosurgical Procedures / trends. Practice Patterns, Physicians'

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):753-7 [1402964.001]
  • [Cites] Int J Qual Health Care. 1999 Jun;11(3):187-92 [10435838.001]
  • [Cites] Br J Gen Pract. 1999 Jan;49(438):35-8 [10622014.001]
  • [Cites] BMC Health Serv Res. 2003 Dec 19;3(1):23 [14687426.001]
  • [Cites] Epilepsia. 2002 Feb;43(2):175-82 [11903465.001]
  • [Cites] Epilepsy Curr. 2002 Jul;2(4):105-107 [15309132.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):62-9 [8315470.001]
  • [Cites] J Neurooncol. 1992 Jan;12(1):53-68 [1541979.001]
  • [Cites] Arch Neurol. 1995 Jul;52(7):717-24 [7619029.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Surg Neurol. 1989 May;31(5):361-4 [2711309.001]
  • [Cites] Acta Neurochir (Wien). 1990;103(1-2):47-51 [2360466.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1621-4 [3171627.001]
  • [Cites] Neurosurgery. 1985 Mar;16(3):290-2 [2984599.001]
  • [Cites] Surg Neurol. 1981 Dec;16(6):399-401 [7330758.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):510-7 [2864654.001]
  • [Cites] J Neurotrauma. 2000 Jun-Jul;17(6-7):549-53 [10937900.001]
  • [Cites] Can J Neurol Sci. 2003 May;30(2):106-12 [12774949.001]
  • (PMID = 16193395.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down






Advertisement